PubRank

Andrew N Phillips

Author PubWeight™ 244.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 16.56
2 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015 15.06
3 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009 14.01
4 Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003 12.23
5 Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006 9.21
6 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008 8.73
7 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008 6.73
8 Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003 5.61
9 Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005 5.20
10 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006 5.00
11 HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009 4.19
12 HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012 4.08
13 Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004 3.59
14 The role of HIV in serious diseases other than AIDS. AIDS 2008 3.39
15 Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008 3.35
16 Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012 3.09
17 A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002 2.87
18 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010 2.85
19 Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004 2.76
20 Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005 2.45
21 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 2.27
22 Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009 2.20
23 HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2010 2.06
24 Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005 1.93
25 Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009 1.88
26 Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008 1.83
27 Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005 1.80
28 Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002 1.79
29 Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012 1.76
30 Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002 1.74
31 Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006 1.71
32 Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004 1.70
33 Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010 1.69
34 Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006 1.69
35 Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002 1.63
36 When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003 1.60
37 Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010 1.57
38 Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005 1.52
39 Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006 1.52
40 Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007 1.51
41 Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003 1.44
42 Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 2005 1.42
43 The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004 1.39
44 Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003 1.34
45 Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010 1.33
46 Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006 1.27
47 Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis 2012 1.25
48 Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009 1.23
49 Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002 1.22
50 Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis 2009 1.21
51 Does ART prevent HIV transmission among MSM? AIDS 2012 1.20
52 Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr 2010 1.20
53 Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS 2010 1.17
54 Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005 1.16
55 Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002 1.15
56 Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007 1.15
57 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010 1.12
58 Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS 2008 1.11
59 The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003 1.09
60 Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009 1.09
61 Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS 2005 1.07
62 Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008 1.07
63 The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 2007 1.07
64 CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009 1.07
65 Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007 1.06
66 'Test-and-treat': the end of the HIV epidemic? Curr Opin Infect Dis 2011 1.06
67 Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003 1.04
68 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005 1.03
69 Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002 1.02
70 Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007 1.02
71 Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008 1.00
72 Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 2008 0.99
73 Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013 0.98
74 Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One 2012 0.98
75 HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006 0.96
76 The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics. PLoS One 2013 0.96
77 Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004 0.96
78 A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 2007 0.96
79 Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003 0.95
80 Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007 0.95
81 Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013 0.94
82 Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007 0.94
83 Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002 0.93
84 Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet 2002 0.93
85 Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007 0.91
86 A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther 2006 0.90
87 Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr 2010 0.89
88 Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008 0.89
89 Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther 2004 0.89
90 HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 2004 0.88
91 Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004 0.88
92 Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS 2011 0.87
93 Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther 2002 0.87
94 Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS 2014 0.87
95 Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antivir Ther 2013 0.87
96 CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS 2013 0.86
97 Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther 2010 0.86
98 Predicting the potential benefits of early initiation of ART: time to do a trial to find out. Curr Opin HIV AIDS 2009 0.85
99 Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004 0.85
100 Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS 2013 0.84
101 Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006 0.84
102 Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. J Acquir Immune Defic Syndr 2007 0.84
103 The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther 2005 0.83
104 Haemoglobin and anaemia in the SMART study. Antivir Ther 2011 0.82
105 Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings. Arch Intern Med 2009 0.82
106 Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS 2014 0.82
107 Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005 0.82
108 Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. HIV Med 2007 0.81
109 Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. PLoS One 2011 0.81
110 Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011 0.81
111 The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005 0.80
112 The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS 2002 0.80
113 Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J Infect Dis 2007 0.80
114 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. J Acquir Immune Defic Syndr 2013 0.79
115 Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS 2003 0.79
116 Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review. AIDS 2016 0.78
117 A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics. JMIR Res Protoc 2016 0.78
118 Prevalence of recreational drug use is indiscriminate across antiretroviral regimens of differing drug-drug interactions among MSM. AIDS 2016 0.77
119 Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? AIDS 2015 0.77
120 Update on HIV in Western Europe. Curr HIV/AIDS Rep 2014 0.77
121 The role of individual-based models in understanding the potential impact of antiretroviral therapy for prevention. AIDS 2012 0.77
122 HIV resistance testing and detected drug resistance in Europe. AIDS 2015 0.76
123 Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs. BMJ 2004 0.75
124 Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. Clin Infect Dis 2009 0.75
125 Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study). JMIR Res Protoc 2016 0.75
126 Rescue of severely immunocompromised HIV-positive persons. J Infect Dis 2010 0.75
127 The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. AIDS 2016 0.75
128 Twenty five years of HIV infection in haemophilic men in Britain: an observational study. BMJ 2005 0.75
129 Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antivir Ther 2011 0.75
130 The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial. AIDS 2016 0.75
131 Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. J Acquir Immune Defic Syndr 2017 0.75
132 A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006 0.75
133 Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immune Defic Syndr 2002 0.75